首页 > 最新文献

Journal of Clinical and Aesthetic Dermatology最新文献

英文 中文
Economic and Clinical Value Delivered by Dermatology Trainees From 2016 to 2023. 2016 - 2023年皮肤科实习生的经济价值与临床价值
Q2 Medicine Pub Date : 2025-09-01
Albert E Zhou, Christian Gronbeck, Brett Sloan, Hao Feng
{"title":"Economic and Clinical Value Delivered by Dermatology Trainees From 2016 to 2023.","authors":"Albert E Zhou, Christian Gronbeck, Brett Sloan, Hao Feng","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 9","pages":"19-20"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What Are Topical Adaptogens? A Systematic Review and Proposed System to Identify and Categorize Skin Adaptogens in Dermatology. 什么是局部适应原?在皮肤病学中识别和分类皮肤适应原的系统综述和建议系统。
Q2 Medicine Pub Date : 2025-09-01
Marianna Blyumin-Karasik, Jessica Colon, Daniel Karasik, Sylvie Nguyen, Heather Woolery-Lloyd, Edward Lain

Background: Skin adaptogens are a class of active ingredients that can enhance human adaptation by reducing the deleterious effects of intrinsic and extrinsic stressors. Adaptogens' homeostatic actions enhance the skin's resilience, improving skin health and quality. Most of the investigated and identified adaptogens are botanicals and have relevant applications in dermatology, but their precise mechanism of action (MOA) and classification are yet to be determined.

Methods: Articles related to botanical adaptogens published within the last 20 years were obtained from the Ovid, Cochrane, and PubMed databases. Studies had to include botanicals studied topically on the skin and classified as adaptogens in the paper. The systematic search resulted in 643 articles, and after the selection process, 12 studies were chosen for the systematic review.

Results: Twelve scientific papers identified 29 topical adaptogens with capabilities of promoting skin health and cosmesis via homeostatic mechanisms. These papers reviewed the effects of topical adaptogens on photodamage, photoaging, antioxidant activity, antimicrobial activity, inflammation, metabolic activity, hormones, and regenerative effects. We propose an identification and classification system of topical adaptogens. We also list currently identified topical adaptogens in the literature and propose other potential cutaneous adaptogens.

Conclusion: We have identified 29 skin adaptogens and categorized them based on their MOA: safe, homeostatic, and multitargeted. We propose this classification system as a guide to identify and catalog topical adaptogens in dermatology.

背景:皮肤适应原是一类可以通过减少内在和外在应激源的有害影响来增强人体适应能力的活性成分。适应原的自我平衡作用增强皮肤的弹性,改善皮肤的健康和质量。已研究和鉴定的适应原大多为植物性药物,在皮肤病学中有相关应用,但其确切的作用机制(MOA)和分类尚未确定。方法:从Ovid、Cochrane和PubMed数据库中获取近20年来发表的与植物适应原相关的文章。研究必须包括在皮肤上局部研究的植物性药物,并在论文中归类为适应原。系统检索结果为643篇,经过筛选过程,选择12篇研究纳入系统评价。结果:12篇科学论文确定了29种局部适应原,它们通过体内平衡机制促进皮肤健康和美容。本文综述了外用适应原对光损伤、光老化、抗氧化活性、抗菌活性、炎症、代谢活性、激素和再生作用的影响。我们提出了一个局部适应原的识别和分类系统。我们还列出了文献中目前发现的局部适应原,并提出了其他潜在的皮肤适应原。结论:我们鉴定了29种皮肤适应原,并根据它们的MOA进行了分类:安全、稳态和多靶向。我们提出这个分类系统作为一个指南,以识别和目录局部适应原在皮肤科。
{"title":"What Are Topical Adaptogens? A Systematic Review and Proposed System to Identify and Categorize Skin Adaptogens in Dermatology.","authors":"Marianna Blyumin-Karasik, Jessica Colon, Daniel Karasik, Sylvie Nguyen, Heather Woolery-Lloyd, Edward Lain","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Skin adaptogens are a class of active ingredients that can enhance human adaptation by reducing the deleterious effects of intrinsic and extrinsic stressors. Adaptogens' homeostatic actions enhance the skin's resilience, improving skin health and quality. Most of the investigated and identified adaptogens are botanicals and have relevant applications in dermatology, but their precise mechanism of action (MOA) and classification are yet to be determined.</p><p><strong>Methods: </strong>Articles related to botanical adaptogens published within the last 20 years were obtained from the Ovid, Cochrane, and PubMed databases. Studies had to include botanicals studied topically on the skin and classified as adaptogens in the paper. The systematic search resulted in 643 articles, and after the selection process, 12 studies were chosen for the systematic review.</p><p><strong>Results: </strong>Twelve scientific papers identified 29 topical adaptogens with capabilities of promoting skin health and cosmesis via homeostatic mechanisms. These papers reviewed the effects of topical adaptogens on photodamage, photoaging, antioxidant activity, antimicrobial activity, inflammation, metabolic activity, hormones, and regenerative effects. We propose an identification and classification system of topical adaptogens. We also list currently identified topical adaptogens in the literature and propose other potential cutaneous adaptogens.</p><p><strong>Conclusion: </strong>We have identified 29 skin adaptogens and categorized them based on their MOA: safe, homeostatic, and multitargeted. We propose this classification system as a guide to identify and catalog topical adaptogens in dermatology.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 9","pages":"28-35"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Confluent and Reticulated Papillomatosis With Calcipotriene and Tretinoin: A Novel Topical Regimen. 钙三烯和维甲酸成功治疗融合网状乳头状瘤病:一种新的局部治疗方案。
Q2 Medicine Pub Date : 2025-09-01
Rajiv Nathoo, Fahad Siddiqui

Confluent and reticulated papillomatosis (CARP) is a rare dermatosis of uncertain etiology characterized by scaly, hyperpigmented papules that coalesce into reticulated plaques, typically affecting the upper trunk of adolescents and young adults. While oral minocycline remains the most established treatment, relapse and adverse effects often are limiting factors. We present the case of a 25-year-old male patient with an 18-month history of CARP who experienced initial improvement with oral antibiotics but discontinued systemic therapy due to side effects. The patient was successfully treated with a novel topical regimen of calcipotriene 0.005% cream daily and tretinoin 0.05% cream nightly, achieving complete clearance after 3 months of consistent use without adverse effects. This case supports the role of disordered keratinization in CARP and demonstrates that topical calcipotriene and tretinoin may offer a safe and effective treatment alternative for patients who cannot tolerate or prefer to avoid systemic antibiotics.

融合网状乳头状瘤病(CARP)是一种病因不明的罕见皮肤病,其特征是鳞状、色素沉着的丘疹合并成网状斑块,通常影响青少年和年轻人的上干。虽然口服二甲胺四环素仍然是最成熟的治疗方法,但复发和不良反应往往是限制因素。我们报告了一位25岁的男性患者,他有18个月的鲤鱼病史,最初通过口服抗生素得到改善,但由于副作用而停止全身治疗。患者成功地接受了一种新的局部治疗方案,即每天0.005%的钙三烯乳膏和每晚0.05%的维甲酸乳膏,在连续使用3个月后完全清除,无不良反应。本病例支持了角化紊乱在CARP中的作用,并表明局部钙三烯和维甲酸可能为不能耐受或倾向于避免全身抗生素的患者提供一种安全有效的治疗选择。
{"title":"Successful Treatment of Confluent and Reticulated Papillomatosis With Calcipotriene and Tretinoin: A Novel Topical Regimen.","authors":"Rajiv Nathoo, Fahad Siddiqui","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Confluent and reticulated papillomatosis (CARP) is a rare dermatosis of uncertain etiology characterized by scaly, hyperpigmented papules that coalesce into reticulated plaques, typically affecting the upper trunk of adolescents and young adults. While oral minocycline remains the most established treatment, relapse and adverse effects often are limiting factors. We present the case of a 25-year-old male patient with an 18-month history of CARP who experienced initial improvement with oral antibiotics but discontinued systemic therapy due to side effects. The patient was successfully treated with a novel topical regimen of calcipotriene 0.005% cream daily and tretinoin 0.05% cream nightly, achieving complete clearance after 3 months of consistent use without adverse effects. This case supports the role of disordered keratinization in CARP and demonstrates that topical calcipotriene and tretinoin may offer a safe and effective treatment alternative for patients who cannot tolerate or prefer to avoid systemic antibiotics.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 9","pages":"55-57"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can the Pursuit of an Ageless Face Redefine Medicine? Exploring Dermatology's Role in the Quest for Immortality. 对不老脸的追求能否重新定义医学?探索皮肤病学在追求不朽中的作用。
Q2 Medicine Pub Date : 2025-08-01
Aaron Cheng, Harrison Shawa, Zachary Uttke, David G Cotter

Recent years have witnessed significant growth in aging research due to groundbreaking discoveries in gerotherapeutics and an ever-increasing interest in longevity. Such advances beg the question, what if the physical and functional declines we associate with aging were no longer inevitable, but instead treatable through the next frontier of medical innovation? In this article, we explore the broader social and ethical implications of advancing healthspan and mitigating age-related decline. We also highlight dermatology's unique role as a catalyst of aging research, serving as a model for integrating aesthetic and functional innovations. Finally, we discuss the curious role and the ethical challenges of the aesthetic dermatology industry in the healthspan debate.

近年来,由于老年治疗的突破性发现和对长寿的兴趣不断增加,衰老研究取得了显着增长。这些进步回避了一个问题,如果我们与衰老相关的身体和功能衰退不再是不可避免的,而是可以通过医学创新的下一个前沿来治疗呢?在这篇文章中,我们探讨了更广泛的社会和伦理意义,促进健康和减轻年龄相关的下降。我们还强调皮肤病学作为衰老研究催化剂的独特作用,作为整合美学和功能创新的典范。最后,我们讨论了美容皮肤科行业在健康跨度辩论中的奇怪作用和伦理挑战。
{"title":"Can the Pursuit of an Ageless Face Redefine Medicine? Exploring Dermatology's Role in the Quest for Immortality.","authors":"Aaron Cheng, Harrison Shawa, Zachary Uttke, David G Cotter","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent years have witnessed significant growth in aging research due to groundbreaking discoveries in gerotherapeutics and an ever-increasing interest in longevity. Such advances beg the question, what if the physical and functional declines we associate with aging were no longer inevitable, but instead treatable through the next frontier of medical innovation? In this article, we explore the broader social and ethical implications of advancing healthspan and mitigating age-related decline. We also highlight dermatology's unique role as a catalyst of aging research, serving as a model for integrating aesthetic and functional innovations. Finally, we discuss the curious role and the ethical challenges of the aesthetic dermatology industry in the healthspan debate.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 8","pages":"27-29"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Colony-forming Units of Malassezia spp. in Patients with Atopic Dermatitis with and without Response to Systemic Treatment. 特应性皮炎患者中马拉色菌菌落形成单位对全身治疗的反应和不反应的比较。
Q2 Medicine Pub Date : 2025-08-01
Carlos Daniel Sánchez-Cárdenas, Liliana Godinez Aldrete, Zaira Ruelas Guzmán, Diana Carolina Vega Sánchez, Mayra Itzel Cano Viveros, Nancy Pulido Díaz, Roberto Arenas, Gabriela Moreno-Coutiño

Introduction: It has been proposed that some cases of refractory atopic dermatitis are caused by an overgrowth of Malassezia spp. This study aimed to compare the colony-forming units of Malassezia spp. in patients with AD who were grouped based on their responsiveness to systemic treatment.

Methods: This prospective, cross-sectional, and comparative study was conducted in patients with AD who were treated with prednisone, cyclosporine, and methotrexate, and separated in two groups, those with and those without response to their treatments, and who had not received treatment with antifungals (topical or systemic) within the prior six months. Scoring Atopic Dermatitis (SCORAD) was determined to evaluate disease severity and therapy response. A sample of epidermal cells from the glabellar region was obtained by scraping for direct examination with methylene blue and m-Dixon agar culture in search of colony-forming units. Fisher's exact test and Mann-Whitney U test were performed to compare the groups.

Results: A total of 15 patients were included in each group. The majority of the group who were refractory to treatment were women (60%), while the non-refractory group were predominantly men (66.7%). In addition, 73.3 percent of subjects with therapeutic resistance presented fungal growth in the cultures compared to 40 percent in the non-resistant group. A significant difference was found between direct examination (p=0.000) and colony-forming units of Malassezia spp. (p=0.016) in patients with AD resistant to systemic treatment.

Conclusion: Patients with AD resistant to systemic treatment had a higher count of colony-forming units of Malassezia spp. Therefore, we propose intentionally seeking this fungus in patients with therapeutic failure to eliminate its overpopulation.

导语:有人提出,一些难治性特应性皮炎病例是由马拉色菌的过度生长引起的,本研究旨在比较AD患者中马拉色菌的菌落形成单位,这些患者根据对全身治疗的反应性进行分组。方法:这项前瞻性、横断性和比较研究是在接受强的松、环孢素和甲氨蝶呤治疗的AD患者中进行的,并将其分为两组,一组对治疗有反应,另一组对治疗无反应,并且在过去6个月内未接受抗真菌药物(局部或全身)治疗。测定特应性皮炎评分(SCORAD)以评估疾病严重程度和治疗反应。刮取glabella区表皮细胞样本,用亚甲基蓝和m-Dixon琼脂培养直接检查,寻找集落形成单位。采用Fisher精确检验和Mann-Whitney U检验进行组间比较。结果:每组15例患者。治疗难治性组以女性为主(60%),非难治性组以男性为主(66.7%)。此外,73.3%的治疗耐药受试者在培养物中出现真菌生长,而非耐药组的这一比例为40%。在对全身治疗有抵抗力的AD患者中,直接检查(p=0.000)和马拉色菌菌落形成单位(p=0.016)之间存在显著差异。结论:对全身治疗有耐药性的AD患者有较高的马拉色菌菌落形成单位,因此,我们建议在治疗失败的患者中有意寻找这种真菌,以消除其过剩的种群。
{"title":"Comparison of Colony-forming Units of <i>Malassezia spp</i>. in Patients with Atopic Dermatitis with and without Response to Systemic Treatment.","authors":"Carlos Daniel Sánchez-Cárdenas, Liliana Godinez Aldrete, Zaira Ruelas Guzmán, Diana Carolina Vega Sánchez, Mayra Itzel Cano Viveros, Nancy Pulido Díaz, Roberto Arenas, Gabriela Moreno-Coutiño","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>It has been proposed that some cases of refractory atopic dermatitis are caused by an overgrowth of <i>Malassezia</i> spp. This study aimed to compare the colony-forming units of <i>Malassezia</i> spp. in patients with AD who were grouped based on their responsiveness to systemic treatment.</p><p><strong>Methods: </strong>This prospective, cross-sectional, and comparative study was conducted in patients with AD who were treated with prednisone, cyclosporine, and methotrexate, and separated in two groups, those with and those without response to their treatments, and who had not received treatment with antifungals (topical or systemic) within the prior six months. Scoring Atopic Dermatitis (SCORAD) was determined to evaluate disease severity and therapy response. A sample of epidermal cells from the glabellar region was obtained by scraping for direct examination with methylene blue and m-Dixon agar culture in search of colony-forming units. Fisher's exact test and Mann-Whitney U test were performed to compare the groups.</p><p><strong>Results: </strong>A total of 15 patients were included in each group. The majority of the group who were refractory to treatment were women (60%), while the non-refractory group were predominantly men (66.7%). In addition, 73.3 percent of subjects with therapeutic resistance presented fungal growth in the cultures compared to 40 percent in the non-resistant group. A significant difference was found between direct examination (<i>p</i>=0.000) and colony-forming units of <i>Malassezia</i> spp. (<i>p</i>=0.016) in patients with AD resistant to systemic treatment.</p><p><strong>Conclusion: </strong>Patients with AD resistant to systemic treatment had a higher count of colony-forming units of <i>Malassezia</i> spp. Therefore, we propose intentionally seeking this fungus in patients with therapeutic failure to eliminate its overpopulation.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 8","pages":"41-43"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced Clinical Outcomes and Treatment Adherence in Patients Using Compounded Topical Minoxidil to Treat Androgenetic and Traction Alopecia. 使用复合外用米诺地尔治疗雄激素性和牵引性脱发患者的临床疗效和治疗依从性增强。
Q2 Medicine Pub Date : 2025-08-01
Jiana Wyche, Crystal Aguh

Introduction: This study highlights the experiences and clinical outcomes of Black women treated with compounded topical minoxidil (CTM), containing a steroid and retinoid, compared to over the counter (OTC) minoxidil.

Methods: A retrospective chart review included 66 Black women treated at Johns Hopkins Hospital between 2020 and 2024. Patients previously used OTC minoxidil and were currently using CTM. Data collected included patient demographics, formulation, side effects, follow-up visits, and patient-reported outcomes. Adherence was assessed at follow-up appointments based on self-reported CTM use.

Results: Of the 66 patients, 33.3 percent had traction alopecia (TA), 37.9 percent had androgenetic alopecia (AGA), and 28.8 percent had combined AGA and TA. Side effects from OTC minoxidil were reported by 21.2 percent of patients, with scalp irritation being the most common. Only 10.6 percent of patients reported side effects while using CTM, with 4.5 percent reporting scalp irritation and four reporting hypertrichosis. After receiving treatment with CTM for at least six months, patients had an overall adherence rate of 84.7 percent, compared to only 44.7 percent of patients who adhered to OTC minoxidil (p<0.001). Clinical improvement was reported by 69.6 percent of patients using CTM, compared to 45.0 percent of patients using OTC minoxidil (p<0.001).

Discussion: CTM was associated with higher adherence, fewer side effects, and clinical improvement in majority of patients treated with CTM compared to their previous OTC minoxidil use.

Limitations: This is a single institution study.

Conclusion: When treating AGA or TA in Black women, special consideration should be taken when selecting minoxidil formulation, as it may have an impact on adherence and efficacy.

本研究强调了黑人妇女使用含有类固醇和类维生素a的复合外用米诺地尔(CTM)与非处方(OTC)米诺地尔治疗的经验和临床结果。方法:对2020年至2024年期间在约翰霍普金斯医院接受治疗的66名黑人妇女进行回顾性分析。患者以前使用OTC米诺地尔,目前正在使用中西医结合治疗。收集的数据包括患者人口统计、配方、副作用、随访和患者报告的结果。依从性在随访预约时根据自我报告的CTM使用情况进行评估。结果:66例患者中,牵引性脱发(TA)占33.3%,雄激素性脱发(AGA)占37.9%,AGA和TA合并占28.8%。21.2%的患者报告了OTC米诺地尔的副作用,头皮刺激是最常见的。只有10.6%的患者报告了使用CTM的副作用,4.5%的患者报告了头皮刺激,4人报告了多毛。在接受CTM治疗至少6个月后,患者的总体依从率为84.7%,相比之下,只有44.7%的患者坚持使用OTC米诺地尔(ppDiscussion:与之前使用OTC米诺地尔相比,大多数接受CTM治疗的患者的依从性更高,副作用更少,临床改善。局限性:这是一项单机构研究。结论:在治疗黑人女性AGA或TA时,米诺地尔处方的选择应特别考虑,因为它可能影响依从性和疗效。
{"title":"Enhanced Clinical Outcomes and Treatment Adherence in Patients Using Compounded Topical Minoxidil to Treat Androgenetic and Traction Alopecia.","authors":"Jiana Wyche, Crystal Aguh","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>This study highlights the experiences and clinical outcomes of Black women treated with compounded topical minoxidil (CTM), containing a steroid and retinoid, compared to over the counter (OTC) minoxidil.</p><p><strong>Methods: </strong>A retrospective chart review included 66 Black women treated at Johns Hopkins Hospital between 2020 and 2024. Patients previously used OTC minoxidil and were currently using CTM. Data collected included patient demographics, formulation, side effects, follow-up visits, and patient-reported outcomes. Adherence was assessed at follow-up appointments based on self-reported CTM use.</p><p><strong>Results: </strong>Of the 66 patients, 33.3 percent had traction alopecia (TA), 37.9 percent had androgenetic alopecia (AGA), and 28.8 percent had combined AGA and TA. Side effects from OTC minoxidil were reported by 21.2 percent of patients, with scalp irritation being the most common. Only 10.6 percent of patients reported side effects while using CTM, with 4.5 percent reporting scalp irritation and four reporting hypertrichosis. After receiving treatment with CTM for at least six months, patients had an overall adherence rate of 84.7 percent, compared to only 44.7 percent of patients who adhered to OTC minoxidil (<i>p</i><0.001). Clinical improvement was reported by 69.6 percent of patients using CTM, compared to 45.0 percent of patients using OTC minoxidil (<i>p</i><0.001).</p><p><strong>Discussion: </strong>CTM was associated with higher adherence, fewer side effects, and clinical improvement in majority of patients treated with CTM compared to their previous OTC minoxidil use.</p><p><strong>Limitations: </strong>This is a single institution study.</p><p><strong>Conclusion: </strong>When treating AGA or TA in Black women, special consideration should be taken when selecting minoxidil formulation, as it may have an impact on adherence and efficacy.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 8","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing Advanced Squamous Cell Carcinoma: A Guide for the Dermatology Clinician. 管理晚期鳞状细胞癌:皮肤科临床医生指南。
Q2 Medicine Pub Date : 2025-08-01
Joshua Burshtein, Todd Schlesinger

Objective: Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer. Advanced cSCCs encompass locally advanced cSCC (laCSCC), including primary or recurrent tumors that are not amenable to curative surgery or radiation therapy, and metastatic (locoregional or distant) cSCCs (mCSCC). With the development of immunotherapies (eg, PD-1 inhibitors), there may be an enhanced opportunity to effectively treat advanced cSCC. We aim to review the current literature on therapeutic options and outline treatment strategies to optimize care for patients with advanced cSCC.

Methods: A comprehensive literature search was completed using the keywords "advanced cutaneous squamous cell carcinoma," "treatment," "surgery," "radiotherapy," "immunotherapy," "PD1-inhibitor," "cemiplimab," and "pembrolizumab". The authors reviewed all studies and included those which addressed the topic of the review.

Results: Advanced cSCCs may not be amenable to surgery or radiotherapy due to size, location, and other aggressive features. Identifying advanced cSCCs and managing patients with multiple tumors and/or those with high tumor burden can be challenging and utilizing current evidence-based guidelines and staging systems can help selection of appropriate therapeutic options. Systemic immunotherapies such as cemiplimab and pembrolizumab have growing evidence for use as a first-line treatment for advanced cSCCs. It is important to understand the adverse event profile of these immunotherapies as utility may be limited by adverse events.

Limitations: This is a review article and is limited by the information available in the published literature. In addition, comparison between studies is limited as varying methodologies were used.

Conclusion: Advanced cSCCs can be difficult to manage and involving a multidisciplinary team is essential. For laCSCCs and mCSCCs not amenable to surgery or radiotherapy, cemiplimab and pembrolizumab can be effective therapeutic options.

目的:皮肤鳞状细胞癌(cSCC)是第二常见的皮肤癌。晚期cSCC包括局部晚期cSCC (laCSCC),包括原发性或复发性肿瘤,不能进行手术或放射治疗,以及转移性(局部或远处)cSCC (mCSCC)。随着免疫疗法(如PD-1抑制剂)的发展,有效治疗晚期cSCC的机会可能会增加。我们的目的是回顾目前关于治疗选择的文献,并概述治疗策略,以优化晚期cSCC患者的护理。方法:以“晚期皮肤鳞状细胞癌”、“治疗”、“手术”、“放疗”、“免疫治疗”、“pd1抑制剂”、“塞米单抗”、“派姆单抗”等关键词进行全面的文献检索。作者回顾了所有的研究,包括那些涉及本综述主题的研究。结果:晚期cSCCs由于其大小、位置和其他侵袭性特征,可能不适合手术或放疗。识别晚期cSCCs和管理多发性肿瘤和/或肿瘤负担高的患者具有挑战性,利用现有的循证指南和分期系统可以帮助选择适当的治疗方案。越来越多的证据表明,全身免疫疗法(如cemiplimab和pembrolizumab)可作为晚期cSCCs的一线治疗。了解这些免疫疗法的不良事件概况是很重要的,因为不良事件可能会限制其效用。局限性:这是一篇综述性文章,受已发表文献中可用信息的限制。此外,由于使用了不同的方法,研究之间的比较受到限制。结论:晚期cSCCs难以管理,需要多学科合作。对于不能接受手术或放疗的laCSCCs和mCSCCs,塞米单抗和派姆单抗是有效的治疗选择。
{"title":"Managing Advanced Squamous Cell Carcinoma: A Guide for the Dermatology Clinician.","authors":"Joshua Burshtein, Todd Schlesinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer. Advanced cSCCs encompass locally advanced cSCC (laCSCC), including primary or recurrent tumors that are not amenable to curative surgery or radiation therapy, and metastatic (locoregional or distant) cSCCs (mCSCC). With the development of immunotherapies (eg, PD-1 inhibitors), there may be an enhanced opportunity to effectively treat advanced cSCC. We aim to review the current literature on therapeutic options and outline treatment strategies to optimize care for patients with advanced cSCC.</p><p><strong>Methods: </strong>A comprehensive literature search was completed using the keywords \"advanced cutaneous squamous cell carcinoma,\" \"treatment,\" \"surgery,\" \"radiotherapy,\" \"immunotherapy,\" \"PD1-inhibitor,\" \"cemiplimab,\" and \"pembrolizumab\". The authors reviewed all studies and included those which addressed the topic of the review.</p><p><strong>Results: </strong>Advanced cSCCs may not be amenable to surgery or radiotherapy due to size, location, and other aggressive features. Identifying advanced cSCCs and managing patients with multiple tumors and/or those with high tumor burden can be challenging and utilizing current evidence-based guidelines and staging systems can help selection of appropriate therapeutic options. Systemic immunotherapies such as cemiplimab and pembrolizumab have growing evidence for use as a first-line treatment for advanced cSCCs. It is important to understand the adverse event profile of these immunotherapies as utility may be limited by adverse events.</p><p><strong>Limitations: </strong>This is a review article and is limited by the information available in the published literature. In addition, comparison between studies is limited as varying methodologies were used.</p><p><strong>Conclusion: </strong>Advanced cSCCs can be difficult to manage and involving a multidisciplinary team is essential. For laCSCCs and mCSCCs not amenable to surgery or radiotherapy, cemiplimab and pembrolizumab can be effective therapeutic options.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 8","pages":"20-26"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Microencapsulated Benzoyl Peroxide on the Skin Microbiome and Clinical Outcomes in Rosacea: An Update on a Randomized, Double-blind, Crossover, Vehicle-controlled Clinical Trial. 微胶囊化过氧化苯甲酰对酒渣鼻患者皮肤微生物组和临床结果的影响:一项随机、双盲、交叉、载体对照临床试验的最新进展
Q2 Medicine Pub Date : 2025-08-01
Yvonne Nong, Jeffrey Sugarman, Jean Philippe York, Ofra Levy-Hacham, Dawnica Nadora, Rinat Mizrahi, Aidan Galati, Richard L Gallo, Raja K Sivamani

Objective: We sought to evaluate changes in skin microbiome biodiversity and correlation with rosacea improvement of microencapsulated benzoyl peroxide (E-BPO) versus vehicle cream in rosacea patients in a 12-week crossover study with a no-treatment period of four weeks (Week 16).

Methods: This was a randomized, double-blind, single-center, crossover, vehicle-controlled evaluation of E-BPO on the skin microbiome in rosacea. Thirty-one participants had facial rosacea with global severity of 3 or 4 on the Investigator's Global Assessment (IGA) scale. Participants were randomly assigned to two groups. The E-BPO/vehicle group applied E-BPO for eight weeks, then vehicle for four weeks. The vehicle/E-BPO group applied vehicle for eight weeks, then E-BPO for four weeks. Clinical assessments were performed using IGA, inflammatory rosacea scale, and erythema scale. Determination of change in skin microbiome was based on facial swab sampling.

Results: Shifts in the microbiome correlated with improvements in IGA, inflammatory rosacea, and erythema. At Week 8, similar bacterial species diversity profiles were observed among all participants. After crossover of the vehicle/E-BPO group at eight weeks to E-BPO, the relative abundance of Staphylococcus epidermidis was markedly lowered, and the relative abundance of Cutibacterium acnes was slightly increased. In the E-BPO/vehicle group, the relative abundance of S. epidermidis and C. acnes at Weeks 12 and 16 remained at the level observed at Week 8.

Limitations: The study had a short duration, which may not fully capture the long-term effects and durability of E-BPO in real-world clinical practice.

Conclusion: Even after withdrawal at 16 weeks, efficacy and shifts in the skin microbiome were maintained over the duration of the study period with demonstrated clinical improvement and a well-tolerated safety profile.

目的:在一项为期12周的交叉研究中,我们试图评估微胶囊化过氧化苯甲酰(E-BPO)与载体霜对酒渣鼻患者皮肤微生物群多样性的变化及其与酒渣鼻改善的相关性,无治疗期为4周(第16周)。方法:采用随机、双盲、单中心、交叉、车辆对照的方法评价E-BPO对酒渣鼻皮肤微生物组的影响。31名参与者的面部酒渣鼻在研究者的整体评估(IGA)量表上的总体严重程度为3或4。参与者被随机分为两组。E-BPO/整车组应用E-BPO 8周,然后整车4周。整车/E-BPO组给药8周,再给药4周。采用IGA、炎症性酒渣鼻量表和红斑量表进行临床评估。皮肤微生物组变化的测定是基于面部拭子取样。结果:微生物组的改变与IGA、炎症性酒渣鼻和红斑的改善相关。在第8周,在所有参与者中观察到相似的细菌物种多样性概况。整车/E-BPO组在8周与E-BPO交叉后,表皮葡萄球菌的相对丰度明显降低,痤疮角质杆菌的相对丰度略有增加。在E-BPO/vehicle组,第12周和第16周表皮葡萄球菌和痤疮葡萄球菌的相对丰度保持在第8周的水平。局限性:该研究持续时间较短,可能无法完全捕捉到E-BPO在实际临床实践中的长期效果和持久性。结论:即使在16周停药后,在整个研究期间,皮肤微生物组的疗效和变化仍保持不变,表现出临床改善和耐受性良好的安全性。
{"title":"Impact of Microencapsulated Benzoyl Peroxide on the Skin Microbiome and Clinical Outcomes in Rosacea: An Update on a Randomized, Double-blind, Crossover, Vehicle-controlled Clinical Trial.","authors":"Yvonne Nong, Jeffrey Sugarman, Jean Philippe York, Ofra Levy-Hacham, Dawnica Nadora, Rinat Mizrahi, Aidan Galati, Richard L Gallo, Raja K Sivamani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We sought to evaluate changes in skin microbiome biodiversity and correlation with rosacea improvement of microencapsulated benzoyl peroxide (E-BPO) versus vehicle cream in rosacea patients in a 12-week crossover study with a no-treatment period of four weeks (Week 16).</p><p><strong>Methods: </strong>This was a randomized, double-blind, single-center, crossover, vehicle-controlled evaluation of E-BPO on the skin microbiome in rosacea. Thirty-one participants had facial rosacea with global severity of 3 or 4 on the Investigator's Global Assessment (IGA) scale. Participants were randomly assigned to two groups. The E-BPO/vehicle group applied E-BPO for eight weeks, then vehicle for four weeks. The vehicle/E-BPO group applied vehicle for eight weeks, then E-BPO for four weeks. Clinical assessments were performed using IGA, inflammatory rosacea scale, and erythema scale. Determination of change in skin microbiome was based on facial swab sampling.</p><p><strong>Results: </strong>Shifts in the microbiome correlated with improvements in IGA, inflammatory rosacea, and erythema. At Week 8, similar bacterial species diversity profiles were observed among all participants. After crossover of the vehicle/E-BPO group at eight weeks to E-BPO, the relative abundance of <i>Staphylococcus epidermidis</i> was markedly lowered, and the relative abundance of <i>Cutibacterium acnes</i> was slightly increased. In the E-BPO/vehicle group, the relative abundance of <i>S. epidermidis</i> and <i>C. acnes</i> at Weeks 12 and 16 remained at the level observed at Week 8.</p><p><strong>Limitations: </strong>The study had a short duration, which may not fully capture the long-term effects and durability of E-BPO in real-world clinical practice.</p><p><strong>Conclusion: </strong>Even after withdrawal at 16 weeks, efficacy and shifts in the skin microbiome were maintained over the duration of the study period with demonstrated clinical improvement and a well-tolerated safety profile.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 8","pages":"34-40"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultraviolet-Induced Fluorescence Dermoscopy: Game Changers. 紫外线诱导荧光皮肤镜:游戏规则的改变。
Q2 Medicine Pub Date : 2025-08-01
Hana I Nazir, Kathleen E Daly, Elizabeth V Seiverling, Cristian Navarrete-Dechent, Kendall L Buchanan

Ultraviolet-induced fluorescence dermoscopy (UVFD) is a novel diagnostic and visualization technique that enhances visualization of skin dermatoses with ultraviolet (UV) light. UVFD has been used to diagnose dermatoses including bacterial and fungal infections, pigmentary disorders, and skin neoplasms. We present five cases-pitted keratolysis, porokeratosis, molluscum, biopsy site identification, and lentigo maligna-where UVFD alone, compared to traditional polarized dermoscopy (PD) or the unaided clinical exam, served as a "game-changer" in diagnosis and management. Polarized and UV images were captured using a DL5 dermatoscope coupled to a smartphone. In the cases of pitted keratolysis, porokeratosis, and molluscum, we highlight distinct patterns of fluorescence that were readily visualized with UVFD and aided efficient diagnosis, in contrast with more subtle features that were seen under PD. We also demonstrate the utility of UVFD in identification and confirmation of a prior biopsy site in a patient who presented for excision of a skin cancer. Finally, we describe the advantage of UVFD in presurgical margin delineation in a patient with lentigo maligna. In these cases, we show that UVFD facilitates prompt and accurate diagnosis, streamlines appropriate treatment, and has the capacity to reduce the need for unnecessary biopsies. Given the convenience and practicality of a dermatoscope equipped with a UV light, we propose that clinicians would benefit from the use of UVFD as a supplementary tool alongside conventional dermoscopy, rather than as a substitute.

紫外诱导荧光皮肤镜(UVFD)是一种新型的诊断和可视化技术,可以增强紫外线(UV)对皮肤皮肤病的可视化。UVFD已被用于诊断皮肤病,包括细菌和真菌感染、色素紊乱和皮肤肿瘤。我们报告了5个病例——凹点角化、角化孔症、软疣、活检部位鉴定和恶性黄斑——与传统的极化皮肤镜(PD)或独立临床检查相比,UVFD在诊断和治疗方面起到了“游戏规则改变者”的作用。偏振和紫外线图像是通过与智能手机相连的DL5皮肤镜捕获的。在凹陷性角化、多孔性角化和软瘤的病例中,我们强调了明显的荧光模式,与PD下看到的更微妙的特征相比,UVFD很容易观察到并有助于有效诊断。我们还展示了UVFD在识别和确认先前活检部位的实用性,患者谁提出了皮肤癌切除。最后,我们描述的优势UVFD在术前边缘划定患者的恶性慢变性。在这些病例中,我们表明UVFD有助于及时准确的诊断,简化适当的治疗,并有能力减少不必要的活检。鉴于配备紫外光的皮肤镜的便利性和实用性,我们建议临床医生将UVFD作为传统皮肤镜的补充工具,而不是替代品。
{"title":"Ultraviolet-Induced Fluorescence Dermoscopy: Game Changers.","authors":"Hana I Nazir, Kathleen E Daly, Elizabeth V Seiverling, Cristian Navarrete-Dechent, Kendall L Buchanan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ultraviolet-induced fluorescence dermoscopy (UVFD) is a novel diagnostic and visualization technique that enhances visualization of skin dermatoses with ultraviolet (UV) light. UVFD has been used to diagnose dermatoses including bacterial and fungal infections, pigmentary disorders, and skin neoplasms. We present five cases-pitted keratolysis, porokeratosis, molluscum, biopsy site identification, and lentigo maligna-where UVFD alone, compared to traditional polarized dermoscopy (PD) or the unaided clinical exam, served as a \"game-changer\" in diagnosis and management. Polarized and UV images were captured using a DL5 dermatoscope coupled to a smartphone. In the cases of pitted keratolysis, porokeratosis, and molluscum, we highlight distinct patterns of fluorescence that were readily visualized with UVFD and aided efficient diagnosis, in contrast with more subtle features that were seen under PD. We also demonstrate the utility of UVFD in identification and confirmation of a prior biopsy site in a patient who presented for excision of a skin cancer. Finally, we describe the advantage of UVFD in presurgical margin delineation in a patient with lentigo maligna. In these cases, we show that UVFD facilitates prompt and accurate diagnosis, streamlines appropriate treatment, and has the capacity to reduce the need for unnecessary biopsies. Given the convenience and practicality of a dermatoscope equipped with a UV light, we propose that clinicians would benefit from the use of UVFD as a supplementary tool alongside conventional dermoscopy, rather than as a substitute.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 8","pages":"30-33"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Noncompete Agreement: The Current Ordeal and a Possible Solution. 竞业禁止协议:当前的考验和可能的解决方案。
Q2 Medicine Pub Date : 2025-08-01
Anthony Ajegwu, Travis W Blalock
{"title":"The Noncompete Agreement: The Current Ordeal and a Possible Solution.","authors":"Anthony Ajegwu, Travis W Blalock","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 8","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical and Aesthetic Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1